EGFR and non-small cell lung carcinoma: We know that the EGFR mutation Thr790Met is considered pathogenic because it confers resistance to tyrosine kinase inhibitors (Gefitinib TKIs), which are commonly used to treat non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations.